GlassScriptPhysician profile
Dariush Arfaania
NPI 1265543755
$7,628.48
in general payments reported to CMS, 2019-2025
28 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $922 · 2021: $1,119 · 2022: $697 · 2023: $1,324 · 2024: $1,286 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Education: $67.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,344.57 |
| Education | $67.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,629.18 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $650.06 | 2019-2025 | Parsabiv, Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $632.95 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $624.04 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $471.68 | 2019-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $468.20 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $417.61 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $404.49 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $343.54 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $328.17 | 2019-2023 | Korsuva, Velphoro |
| Glaxosmithkline, LLC. | $285.28 | 2021-2025 | Jesduvroq, Benlysta |
| Opko Pharmaceuticals, LLC | $265.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.60 | 2021-2025 | Jardiance |
| Travere Therapeutics, INC. | $159.73 | 2024-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $156.03 | 2019-2024 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $120.63 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $51.78 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $48.36 | 2019 | |
| Calliditas Therapeutics US INC. | $43.74 | 2022-2023 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.75 | 2019-2024 | Xifaxan |
| Ardelyx, INC. | $36.67 | 2024-2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $35.63 | 2022 | |
| Genzyme Corporation | $32.37 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.58 | 2021 | |
| Lilly USA, LLC | $13.39 | 2023 | Jardiance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Arfaania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.